Quarterly Report • May 3, 2023
Quarterly Report
Open in ViewerOpens in native device viewer
| Income Statement Borregaard Group Q1 2023 | |||
|---|---|---|---|
| 1.1-31.3 | 1.1-31.12 | ||
| Amounts in NOK million | 2023 | 2022 | 2022 |
| Operating revenues | 1 850 | 1 615 | 6 881 |
| Operating expenses | -1 415 | -1 215 | -5 238 |
| EBITDA | 435 | 400 | 1 643 |
| Depreciation property, plant and equipment | -114 | -108 | -444 |
| Amortisation intangible assets | -1 | -1 | -5 |
| Other income and expenses | 0 | 0 | -8 |
| Operating profit | 320 | 291 | 1 186 |
| Financial items, net | -28 | -14 | -68 |
| Profit before taxes | 292 | 277 | 1 118 |
| Income tax expence | -71 | -68 | -267 |
| Profit for the period | 221 | 209 | 851 |
| Profit attributable to non-controlling interests | -10 | -8 | -41 |
| Profit attributable to owners of the parent | 231 | 217 | 892 |
| Earnings per share (NOK) | 2,32 | 2,18 | 8,95 |
| EBITDA margin | 23,5 % | 24,8 % | 23,9 % |
| Interim condensed statement of financial position Borregaard Group | ||
|---|---|---|
| 31.3. | 31.12. | |
| Amounts in NOK million | 2023 | 2022 |
| Assets: | ||
| Intangible assets | 82 | 82 |
| Property, plant and equipment | 4 436 | 4 371 |
| Right-of-use assets | 350 | 345 |
| Other assets | 217 | 254 |
| Investments in joint venture/associate company | 136 | 142 |
| Non-current assets | 5 221 | 5 194 |
| Inventories | 1 373 | 1 299 |
| Receivables | 1 560 | 1 387 |
| Cash and cash deposits | 217 | 234 |
| Current assets | 3 150 | 2 920 |
| Total assets | 8 371 | 8 114 |
| Equity and debt: | ||
| Group equity | 4 260 | 4 394 |
| Non-controlling interests | 44 | 51 |
| Equity | 4 304 | 4 445 |
| Provisions and other liabilities | 435 | 295 |
| Interest-bearing liabilities | 1 490 | 1 370 |
| Non-current liabilities | 1 925 | 1 665 |
| Interest-bearing liabilities | 657 | 702 |
| Other current liabilities | 1 485 | 1 302 |
| Current liabilities | 2 142 | 2 004 |
| Equity and liabilities | 8 371 | 8 114 |
| Equity ratio (%): | 51,4 % | 54,8 % |
| Interim condensed cash flow statement Borregaard Group Q1 2023 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1.1-31.3 | 1.1-31.12 | |||||||||
| Amounts in NOK million | 2023 | 2022 | 2022 | |||||||
| Profit before taxes | 292 | 277 | 1 118 | |||||||
| Amortisation, depreciation and impairment charges | 115 | 109 | 449 | |||||||
| Change in net working capital, etc | -193 | -381 | -658 | |||||||
| Dividend/share of profit from JV & associate company | 6 | 0 | 34 | |||||||
| Taxes paid | -109 | -77 | -208 | |||||||
| Cash flow from operating activities | 111 | -72 | 735 | |||||||
| Investments property, plant and equipment and intangible assets * | -107 | -87 | -464 | |||||||
| Investment in associate company | 0 | 0 | 0 | |||||||
| Other capital transactions | 2 | 2 | 9 | |||||||
| Cash flow from Investing activities | -105 | -85 | -455 | |||||||
| Dividends | 0 | 0 | -499 | |||||||
| Proceeds from exercise of options/shares to employees | 41 | 27 | 41 | |||||||
| Buy-back of shares | -41 | -4 | -68 | |||||||
| Gain/(loss) on hedges for net investments in subsidiaries | -58 | 31 | -79 | |||||||
| Net paid to/from shareholders | -58 | 54 | -605 | |||||||
| Proceeds from interest-bearing liabilities | 0 | 100 | 837 | |||||||
| Repayment of interest-bearing liabilities | -14 | -14 | -512 | |||||||
| Change in interest-bearing receivables/other liabilities | 41 | -2 | 78 | |||||||
| Change in net interest-bearing liablities | 27 | 84 | 403 | |||||||
| Cash flow from financing activities | -31 | 138 | -202 | |||||||
| Change in cash and cash equivalents | -25 | -19 | 78 | |||||||
| Cash and cash equivalents at beginning of period | 111 | 5 | 5 | |||||||
| Change in cash and cash equivalents | -25 | -19 | 78 | |||||||
| Currency effects cash and cash equivalents | 19 | -2 | 28 | |||||||
| Cash and cash equivalents at the end of the period | 105 | -16 | 111 | |||||||
| * Investment by category: | ||||||||||
| Replacement investments | 87 | 71 | 359 | |||||||
| Expansion investments including investment in associate company | 20 | 16 | 105 | |||||||
| Total investments including investment in associate company | 107 | 87 | 464 |
| Quarterly segment information Borregaard Group | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating revenues | |||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| Amounts in NOK million | 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 |
| Borregaard | 5 063 | 5 328 | 1 419 | 1 511 | 1 429 | 1 446 | 5 805 | 1 615 | 1 744 | 1 752 | 1 770 | 6 881 | 1 850 |
| BioSolutions | 2 982 | 3 082 | 812 | 885 | 838 | 934 | 3 469 | 948 | 1 098 | 1 007 | 997 | 4 050 | 995 |
| BioMaterials | 1 712 | 1 732 | 523 | 482 | 468 | 405 | 1 878 | 532 | 540 | 558 | 620 | 2 250 | 684 |
| Fine Chemicals | 406 | 543 | 90 | 155 | 132 | 114 | 491 | 143 | 119 | 200 | 170 | 632 | 180 |
| EBITDA | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| Amounts in NOK million | 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 |
| Borregaard | 1 007 | 1 132 | 302 | 416 | 391 | 263 | 1 372 | 400 | 445 | 434 | 364 | 1 643 | 435 |
| BioSolutions | 647 | 632 | 205 | 272 | 251 | 214 | 942 | 261 | 305 | 261 | 159 | 986 | 224 |
| BioMaterials | 234 | 318 | 64 | 102 | 91 | 27 | 284 | 97 | 91 | 101 | 138 | 427 | 127 |
| Fine Chemicals | 126 | 182 | 33 | 42 | 49 | 22 | 146 | 42 | 49 | 72 | 67 | 230 | 84 |
Eliminations - 37 - 29 - 6 - 11 - 9 - 7 - 33 -8 -13 -13 -17 -51 -9
| Depreciations and write downs | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| Amounts in NOK million | 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 |
| Borregaard | - 418 | - 443 | - 106 | - 101 | - 103 | - 106 | - 416 | -108 | -110 | -112 | -114 | -444 | -114 |
| BioSolutions | - 183 | - 206 | - 48 | - 45 | - 47 | - 49 | - 189 | -50 | -53 | -54 | -55 | -212 | -56 |
| BioMaterials | - 203 | - 203 | - 50 | - 47 | - 47 | - 49 | - 193 | -49 | -48 | -49 | -49 | -195 | -49 |
| Fine Chemicals | - 32 | - 34 | - 8 | - 9 | - 9 | - 8 | - 34 | -9 | -9 | -9 | -10 | -37 | -9 |
| Amortisation | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| Amounts in NOK million | 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 |
| Borregaard | - 4 | - 5 | - 1 | - 1 | - 1 | - 1 | - 4 | -1 | -1 | -1 | -2 | -5 | -1 |
| BioSolutions | - 4 | - 5 | - 1 | - 1 | - 1 | - 1 | - 4 | -1 | -1 | -1 | -2 | -5 | -1 |
| BioMaterials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fine Chemicals | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income and expenses | |||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| Amounts in NOK million | 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 |
| Borregaard | -27 | -116 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | -20 | -8 | 0 |
| BioSolutions | -16 | -97 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | -6 | 6 | 0 |
| BioMaterials | -11 | -18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12 | -12 | 0 |
| Fine Chemicals | 0 | - 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -2 | 0 |
| Operating profit (EBIT) | |||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| Amounts in NOK million | 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 |
| Borregaard | 558 | 568 | 195 | 314 | 287 | 156 | 952 | 291 | 346 | 321 | 228 | 1 186 | 320 |
| BioSolutions | 444 | 324 | 156 | 226 | 203 | 164 | 749 | 210 | 263 | 206 | 96 | 775 | 167 |
| BioMaterials | 20 | 97 | 14 | 55 | 44 | - 22 | 91 | 48 | 43 | 52 | 77 | 220 | 78 |
| Fine Chemicals | 94 | 147 | 25 | 33 | 40 | 14 | 112 | 33 | 40 | 63 | 55 | 191 | 75 |
| Hedging effects & currency exposure | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| Amounts in NOK million | 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 |
| Borregaard - EBITDA hedging gains & losses | -76 | -241 | -15 | -4 | -16 | 6 | -29 | 10 | -3 | -23 | -34 | -50 | -48 |
| BioSolutions | -33 | -103 | -5 | -1 | -6 | 1 | -11 | 3 | -5 | -19 | -23 | -44 | -25 |
| BioMaterials | -37 | -116 | -8 | -3 | -8 | 4 | -15 | 5 | 1 | -4 | -9 | -7 | -19 |
| Fine Chemicals | -6 | -22 | -2 | 0 | -2 | 1 | -3 | 2 | 1 | 0 | -2 | 1 | -4 |
| Borregaard - USD EBITDA currency exposure (approx) | 203 | 177 | 198 | 197 | |||||||||
| Borregaard - EUR EBITDA currency exposure (approx) | 98 | 112 | 139 | 147 | |||||||||
| Sales revenues | |||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| Amounts in NOK million | 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 |
| Borregaard | 4 951 | 5 227 | 1 394 | 1 491 | 1 406 | 1 424 | 5 715 | 1 591 | 1 720 | 1 723 | 1 742 | 6 776 | 1 825 |
| BioSolutions | 2 873 | 2 995 | 793 | 865 | 819 | 915 | 3 392 | 929 | 1 072 | 979 | 966 | 3 946 | 973 |
| BioMaterials | 1 679 | 1 695 | 513 | 472 | 457 | 398 | 1 840 | 521 | 530 | 546 | 608 | 2 205 | 674 |
| Fine Chemicals | 400 | 538 | 88 | 154 | 131 | 112 | 485 | 141 | 118 | 198 | 168 | 625 | 178 |
| Eliminations | - 1 | - 1 | 0 | 0 | - 1 | - 1 | - 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| BioSolutions | |||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 | |
| Average gross sales price NOK per mtds | 6 166 | 6 951 | 7 838 | 7 709 | 7 761 | 9 244 | 8 106 | 9 780 | 10 150 | 10 479 | 11 104 | 10 369 | 12 402 |
| Volume (`000 mtds) | 470 | 416 | 90 | 100 | 92 | 84 | 366 | 81 | 90 | 84 | 79 | 334 | 74 |
| Specialities volume (`000 mtds) | 86 | 88 | 89 | 84 | |||||||||
| Contruction volume (`000 mtds) | 209 | 178 | 131 | 117 | |||||||||
| Industrial volume (`000 mtds) | 175 | 150 | 146 | 133 | |||||||||
| BioMaterials | |||||||||||||
| 1.1-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | 1.4-30.6 | 1.7-30.9 | 1.10-31.12 | 1.1-31.12 | 1.1-31.3 | |
| 2019 | 2020 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 | 2022 | 2023 | |
| Average gross sales price NOK per mt | 10 665 | 11 678 | 10 641 | 10 754 | 10 972 | 10 911 | 10 807 | 12 595 | 13 656 | 14 880 | 16 179 | 14 283 | 16 449 |
| Volume (`000 mt) | 153,1 | 148,4 | 47,5 | 42,4 | 40,2 | 34,3 | 164,4 | 39,4 | 36,6 | 34,7 | 36,3 | 147,0 | 40,0 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.